drugset / Trial / NCT04536558
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Phase 3
Unknown
352 enrolled
Sun Yat-sen University
Jiangsu Hansoh Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This is a multicenter, randomized, controlled, double-blind, phase III study.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2021-02-01
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 6 mg | Oral |
| Comparator | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
| Comparator | Ondansetron | Other / unclassified | 8 mg | Intravenous |